https://www.selleckchem.com/pr....oducts/favipiravir-t
PD-1/PD-L1 inhibitors have made unprecedented progress in the treatment of cancer. A systemic search was conducted for randomized controlled trials that compared PD-1/PD-L1 inhibitor monotherapy or combination therapy with nonimmunotherapy. Hazard ratios (HRs) of overall survival (OS) according to the sex, age, ECOG PS, smoking status, liver metastasis, PD-L1 expression, EGFR, and KRAS status of patients were analyzed. Totally, 13 studies with monotherapy and 5 with combination regimens were included, and the pooled HRs of OS
Like
Comment
Share
